What are Regeneron's primary therapeutic areas of focus as of the 1996 fiscal year?

As of the 1996 fiscal year, Regeneron Pharmaceuticals, Inc. was primarily focused on the research and development of therapeutic proteins, aiming to address various unmet medical needs.

What is the company's financial situation depicted in this 10-K, considering its R&D-intensive nature?

This 10-K filing would detail Regeneron's financial position, likely showing significant expenditures on research and development, and a reliance on existing cash reserves and potentially funding from partnerships or equity financing, rather than substantial product revenues.

Are there any key drug candidates or clinical trials highlighted in this filing?

While the exact details are within the full filing, a 10-K from this period would typically highlight the company's lead drug candidates in development and the status of their preclinical and clinical trials, providing insight into the progress of their pipeline.

What are the significant risks Regeneron faced in 1996 as outlined in the filing?

As a biotechnology company in 1996, significant risks for Regeneron would likely include the inherent uncertainties of drug development, the lengthy and costly process of clinical trials, the challenges of obtaining regulatory approvals, potential competition, and the need for ongoing capital to fund operations.

REGN 10-K FY1996 Annual Report — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed its 1996 10-K on March 25, 1997, detailing its financial performance and operational activities for the fiscal year ending December 30, 1996. As a biotechnology company, Regeneron's focus remained on research and development of therapeutic proteins. The filing provides a snapshot of the company's early-stage development and its strategic direction as it navigated the complex and capital-intensive pharmaceutical industry. Investors should note that this filing represents a period when the company was likely heavily investing in its pipeline with limited product revenues. The report would contain detailed information on its lead drug candidates, ongoing clinical trials, research collaborations, and its financial position, including cash reserves and funding strategies. Understanding these aspects is crucial for assessing the long-term growth potential and associated risks of Regeneron at this stage of its corporate evolution.

Key Highlights

1Regeneron Pharmaceuticals, Inc. is reporting on its fiscal year ending December 30, 1996, in this 10-K filing.
2The company is focused on the research and development of therapeutic proteins.
3The filing provides an overview of the company's pipeline and ongoing scientific endeavors.
4Financial information will detail the company's cash position and operational expenses, reflecting significant R&D investments.
5Strategic partnerships and collaborations are likely key components of Regeneron's growth strategy.
6The report will outline the company's approach to addressing unmet medical needs through its drug development efforts.
7Risk factors associated with the biotechnology industry, including clinical trial success and regulatory approvals, are expected to be detailed.

REGENERON PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 1996

Summary

Key Highlights

Frequently Asked Questions